DK2910566T3 - Trunkeret L1 protein af human papillomavirus 11 - Google Patents
Trunkeret L1 protein af human papillomavirus 11 Download PDFInfo
- Publication number
- DK2910566T3 DK2910566T3 DK15160363.6T DK15160363T DK2910566T3 DK 2910566 T3 DK2910566 T3 DK 2910566T3 DK 15160363 T DK15160363 T DK 15160363T DK 2910566 T3 DK2910566 T3 DK 2910566T3
- Authority
- DK
- Denmark
- Prior art keywords
- val
- ser
- leu
- gly
- thr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (17)
1. N-terminalt trunkeret HPV11 L1 protein, der mangler netop de første tre aminosyre ved N-terminalen sammenlignet med vildtype HPV11 L1 protein.
2. N-terminalt trunkeret protein ifølge krav 1, repræsenteret ved en sekvens fremsat i SEQ ID NO:2.
3. Polynukleotid, der koder det N-terminale trunkerede protein ifølge ethvert af krav 1-2.
4. Vektor, som udtrykt ved HPV11 LI proteinet kun omfatter den genetiske information af polynukleotidet ifølge krav 3.
5. Celle omfattende vektoren ifølge krav 4.
6. Sammensætning omfattende det N-terminale trunkerede protein ifølge krav 1 eller 2.
7. HPV11 viruslignende partikel (VLP) omfattende eller bestående af det N-terminalt trunkerede protein ifølge krav 1 eller 2.
8. Fremgangsmåde til fremstilling af det N-terminalt trunkerede HPV11 LI protein ifølge krav 1 eller 2, omfattende: a) eksprimering af et HPV LI gen, der koder det N- terminalt trunkerede FIPV LI protein i et E. coli ekspressionssystem, b) opbrydning af den E. coli, som har eksprimeret det N- terminalt trunkerede HPV LI protein, i en opløsning med en saltkoncentration fra lOOmM til GOOmM, og isolering af det ovenpå flydende, c) sænkning af saltkoncentrationen i det ovenpå flydende af b) til fra 100 mM til og med 0 ved anvendelse af vand eller en svag saltopløsning, og opsamling af et udfældningsprodukt, d) genopløsning af det udfældede af c) i en opløsning ved en saltkoncentration fra 150mM til 2500 mM, tilførsel af et reduktionsmiddel til det, og derefter isolering af den resulterende opløsning, hvori opløsningen indeholder det N-terminalt trunkerede HPV LI protein med en renhed på mindst 50%.
9. Vaccine til forebyggelse af condyloma acuminatum eller HPV infektioner, omfattende HPV11 VLP ifølge krav 7 og bærere eller excipienser, som er anvendelige til vacciner.
10. Vaccine til forebyggelse af condyloma acuminatum eller HPV infektioner ifølge krav 9, yderligere omfattende mindst en HPV VLP valgt fra gruppen bestående af VLP’er af HPV type 6, 16, 18, 31, 33, 45, 52 og 58.
11. Vaccine til forebyggelse af condyloma acuminatum eller HPV infektioner ifølge krav 9, omfattende: en HPV 6 VLP omfattende et protein med en aminosyrese-kvens fremsat i SEQ ID NO:7 og en HPV 11 VLP omfattende et protein med en aminosyresekvens fremsat i SEQ ID NO: 1.
12. Vaccine til forebyggelse af condyloma acuminatum eller HPV infektioner ifølge krav 11, yderligere omfattende en HPV 16 VLP omfattende et protein med en aminosyresekvens fremsat i SEQ ID NO:8 og en HPV 18 VLP omfattende et protein med en aminosyresekvens fremsat i SEQ ID NO: 9.
13. Anvendelse af det N-terminalt trunkerede protein ifølge ethvert af krav 1-2 eller VLP ifølge krav 7 til fremstilling af en vaccine til forebyggelse af condyloma acuminatum eller HPV infektioner.
14. Vaccine omfattende det N-terminalt trunkerede HPV 11 LI protein ifølge ethvert af krav 1-2 eller VLP ifølge krav 7 eller vaccinen ifølge ethvert af krav 9-12 til anvendelse ved forebyggende behandling af et individ med behov for forebyggelse af condyloma acuminatum eller HPV infektioner.
15. Fremgangsmåde ifølge krav 8, yderligere omfattende: e) yderligere rensning af det N-terminalt trunkerede HPV 11 LI protein til en renhed på mindst 50% ved kromatografi, og f) fjernelse af reduktionsmidlet fra HPV 11 LI proteinet fremskaffet i e).
16. Fremgangsmåde til fremstilling af en vaccine til forebyggelse af condyloma acuminatum eller HPV infektioner, omfattende blanding af VLP ifølge krav 7 med bærere eller excipienser, som er anvendelige til vacciner.
17. Fremgangsmåde ifølge krav 16, omfattende blanding af VLP ifølge krav 7 og en eller flere VLP’er af HPV type 6, 16, 18, 31, 33, 45, 52 og 58 med bærere eller excipienser, som er anvendelige til vacciner.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200710105763 | 2007-05-29 | ||
| EP08757380.4A EP2154148B1 (en) | 2007-05-29 | 2008-05-29 | A truncated l1 protein of human papillomavirus 11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2910566T3 true DK2910566T3 (da) | 2016-10-24 |
| DK2910566T5 DK2910566T5 (da) | 2016-11-07 |
Family
ID=40074566
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15160399.0T DK2907821T3 (da) | 2007-05-29 | 2008-05-29 | Fremgangsmåde til fremstilling af et N-terminal trunkeret L1 protein af human papillomavirus (HPV) |
| DK08757380.4T DK2154148T3 (da) | 2007-05-29 | 2008-05-29 | Trunkeret L1 protein af human papillomavirus 11 |
| DK15160363.6T DK2910566T5 (da) | 2007-05-29 | 2008-05-29 | Trunkeret L1 protein af human papillomavirus 11 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15160399.0T DK2907821T3 (da) | 2007-05-29 | 2008-05-29 | Fremgangsmåde til fremstilling af et N-terminal trunkeret L1 protein af human papillomavirus (HPV) |
| DK08757380.4T DK2154148T3 (da) | 2007-05-29 | 2008-05-29 | Trunkeret L1 protein af human papillomavirus 11 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9533035B2 (da) |
| EP (3) | EP2907821B1 (da) |
| CN (1) | CN101343314B (da) |
| BR (1) | BRPI0810959B1 (da) |
| DK (3) | DK2907821T3 (da) |
| HK (2) | HK1124344A1 (da) |
| WO (1) | WO2008145020A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0811016B1 (pt) * | 2007-04-29 | 2021-09-21 | Xiamen Innovax Biotech Co., Ltd. | Proteína li truncada do papiloma vírus humano tipo 16 |
| CN101570571B (zh) | 2007-04-29 | 2012-07-11 | 北京万泰生物药业股份有限公司 | 截短的人乳头瘤病毒18型l1蛋白 |
| DK2154149T3 (da) * | 2007-05-29 | 2019-10-14 | Univ Xiamen | En trunkeret l1-protein af human papillomavirus 6 |
| DK2589604T3 (da) | 2010-07-02 | 2017-01-16 | Univ Xiamen | Trunkeret l1-protein af human papillomavirus type 52 |
| CN102229660B (zh) | 2011-05-25 | 2015-04-22 | 厦门大学 | 截短的人乳头瘤病毒33型l1蛋白 |
| KR101559622B1 (ko) * | 2012-07-30 | 2015-10-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
| CN105039358B (zh) * | 2013-12-03 | 2020-02-28 | 北京康乐卫士生物技术股份有限公司 | 58型重组人乳头瘤病毒病毒样颗粒及其制备方法 |
| KR20180084139A (ko) * | 2015-12-04 | 2018-07-24 | 시아먼 유니버시티 | 11형 인유두종 바이러스 엘1 단백질의 돌연변이체 |
| CN106831960B (zh) * | 2015-12-04 | 2019-11-05 | 厦门大学 | 一种人乳头瘤病毒6型l1蛋白的突变体 |
| WO2021013069A1 (zh) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | 嵌合的人乳头瘤病毒11型l1蛋白 |
| CN114539363B (zh) * | 2020-11-26 | 2023-12-01 | 中国医学科学院基础医学研究所 | 一种c端改造的人乳头瘤病毒11型l1蛋白及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2157932C (en) * | 1993-03-09 | 2011-10-11 | Robert C. Rose | Production of human papillomavirus capsid protein and virus-like particles |
| US20020193565A1 (en) * | 1998-03-27 | 2002-12-19 | Stanley Margaret Anne | Antigen preparation and use |
| US6551597B1 (en) * | 1999-03-18 | 2003-04-22 | President & Fellows Of Harvard College | Vaccine compositions for human papillomavirus |
| WO2003018624A1 (en) | 2001-08-31 | 2003-03-06 | University Of Cape Town | Vectors, constructs, and transgenic plants for hpv-11 and hpv-16 l1 capsid protein |
| GB0206359D0 (en) | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
| WO2003093437A2 (en) * | 2002-05-02 | 2003-11-13 | University Of Rochester | Production of papillomavirus vaccines in plants |
| CN1293093C (zh) * | 2002-08-30 | 2007-01-03 | 马润林 | 乳头瘤病毒衣壳蛋白的原核制备和应用 |
| CN1683010A (zh) | 2005-02-06 | 2005-10-19 | 哈尔滨医科大学 | 人乳头瘤病毒型双价病毒样颗粒混合蛋白抗原及构建方法 |
| CN101153280B (zh) * | 2006-09-29 | 2015-08-19 | 厦门大学 | 从原核生物中纯化人乳头瘤病毒晚期蛋白l1的方法 |
-
2008
- 2008-05-29 EP EP15160399.0A patent/EP2907821B1/en active Active
- 2008-05-29 BR BRPI0810959-1A patent/BRPI0810959B1/pt active IP Right Grant
- 2008-05-29 EP EP08757380.4A patent/EP2154148B1/en active Active
- 2008-05-29 EP EP15160363.6A patent/EP2910566B1/en active Active
- 2008-05-29 WO PCT/CN2008/001049 patent/WO2008145020A1/zh active Application Filing
- 2008-05-29 DK DK15160399.0T patent/DK2907821T3/da active
- 2008-05-29 DK DK08757380.4T patent/DK2154148T3/da active
- 2008-05-29 CN CN200810111389.1A patent/CN101343314B/zh active Active
- 2008-05-29 US US12/601,983 patent/US9533035B2/en active Active
- 2008-05-29 DK DK15160363.6T patent/DK2910566T5/da active
-
2009
- 2009-03-03 HK HK09102007.8A patent/HK1124344A1/zh unknown
-
2015
- 2015-09-15 HK HK15109022.6A patent/HK1208473A1/xx unknown
-
2016
- 2016-11-14 US US15/350,264 patent/US9943586B2/en active Active
-
2018
- 2018-03-19 US US15/924,511 patent/US10537629B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2154148B1 (en) | 2016-06-22 |
| CN101343314A (zh) | 2009-01-14 |
| EP2907821A1 (en) | 2015-08-19 |
| US20180207257A1 (en) | 2018-07-26 |
| EP2154148A1 (en) | 2010-02-17 |
| EP2907821B1 (en) | 2016-12-28 |
| BRPI0810959A2 (pt) | 2015-07-21 |
| EP2910566A1 (en) | 2015-08-26 |
| US9943586B2 (en) | 2018-04-17 |
| US9533035B2 (en) | 2017-01-03 |
| EP2910566B1 (en) | 2016-07-13 |
| HK1208473A1 (en) | 2016-03-04 |
| US20100291141A1 (en) | 2010-11-18 |
| HK1124344A1 (zh) | 2009-07-10 |
| DK2907821T3 (da) | 2017-04-10 |
| DK2910566T5 (da) | 2016-11-07 |
| US10537629B2 (en) | 2020-01-21 |
| EP2154148A4 (en) | 2011-01-05 |
| DK2154148T3 (da) | 2016-09-19 |
| WO2008145020A1 (en) | 2008-12-04 |
| CN101343314B (zh) | 2015-11-25 |
| BRPI0810959B1 (pt) | 2021-06-29 |
| US20170065708A1 (en) | 2017-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2910566T3 (da) | Trunkeret L1 protein af human papillomavirus 11 | |
| DK2154147T3 (da) | Trunkeret L1-protein af human papillomavirus 16 | |
| US9745351B2 (en) | Truncated L1 protein of human papillomavirus type 6 | |
| DK2716653T3 (da) | Trunkeret l1-protein fra humant papillomavirus type 33 | |
| DK2147926T3 (da) | Trunkerede humane papillomavirus type 18 L1 proteiner | |
| US9738691B2 (en) | Truncated L1 protein of human papillomavirus type 58 |